U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H34N2O5.ClH
Molecular Weight 466.998
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of INDOLAPRIL HYDROCHLORIDE

SMILES

Cl.[H][C@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O

InChI

InChIKey=QNSWMJYOGMUVGO-PABIKWFMSA-N
InChI=1S/C24H34N2O5.ClH/c1-3-31-24(30)19(14-13-17-9-5-4-6-10-17)25-16(2)22(27)26-20-12-8-7-11-18(20)15-21(26)23(28)29;/h4-6,9-10,16,18-21,25H,3,7-8,11-15H2,1-2H3,(H,28,29);1H/t16-,18-,19-,20-,21-;/m0./s1

HIDE SMILES / InChI

Description
Curator's Comment: The description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/6323223

Indolapril (CI-907) is a new orally active prodrug of nonsulfhydryl angiotensin-converting enzyme (ACE) inhibitor, developed by Warner-Lambert/Parke-Davis Pharmaceutical Research for treating hypertension. Indolapril is epimer of trandolapril, well-known ACE inhibitor currently in the market for hypertension treatment. Indolapril (Monoester form) and it’s active component (diacid form) produced concentration related ACE inhibition in guinea-pig serum (IC50 for monoester -- 0.1 mkM and for diacid -- 2.6 nM). In isolated rabbit aortic rings and in rat and dog autonomic studies, Indolapril is highly specific in suppressing the contractile or pressor responses to angiotensin I. In two-kidney, one-clip Goldblatt hypertensive rats, single daily doses (0.03-30 mg/kg p.o.) produced dose-dependent decreases in blood pressure; 3 mg/kg lowered blood pressure to normotensive levels. In the spontaneously hypertensive rat, subacute administration of Indolapril produced the same decrease in blood pressure as that obtained in the renal hypertensive rat. In diuretic-pretreated renal hypertensive dogs, 10 mg/kg normalized blood pressure. For equivalent drops in blood pressure, heart rate increases were less in Indolapril than in enalapril-treated renal hypertensive dogs. No side effects were observed with CI-907 in any of the conscious animals. The antihypertensive response to Indolapril (0.03-1.0 mg/kg p.o.) was found to correlate with inhibition of vascular tissue ACE, but not plasma or brain ACE in two-kidney, one-clip renal hypertensive rats.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.1 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Antihypertensive effects of CI-907 (indolapril): a novel nonsulfhydryl angiotensin converting enzyme inhibitor.
1984 Feb
Patents

Patents

Sample Use Guides

Rat: 0.03-1.0 mg/kg p.o
Route of Administration: Oral
In Vitro Use Guide
The in vitro inhibition ofvascular ACE was determined in isolated circular aortic segments of adult New Zealand rabbits. After cranio-vertebral dislocation, the descending thoracic aorta was removed, cut into 4- to 5 mm-wide circular segments and suspended in tissue baths containing physiological salt solution consisting of (millimolar): NaCl, 118.2; KC1, 4.6; KH2PO4, 1.2; NaHCO3, 24.8; MgSO4, 1.2; CaCl2, 2.5; Ca-disodium EDTA, 0.026; and dextrose, 10.0. Tissues were oxygenated with 95% 025% CO2 and maintained at pH 7.3 to 7.5 and at a temperature of 37C. An optimal initial force of 2 g was used and contractions were measured isometrically with a Grass FTO3 force-displacement transducer connected to a Brush 260 polygraph. After a 1.5-hr equilibration period, cumulative concentration-response curves were obtained to angiotensin I, angiotensin II, norepinephrine and potassium chloride. Once maximum force was reached with each agonist, tissues were rinsed until base-line force was reestablished. Only one agonist and one concentration of CI-907 (Indolapril) were used per tissue. To minimize tachyphylazis to agonists, which occasionaily occurs between first and second concentration-response curves, three curves were obtained. The first curve was discarded, the second curve served as the control and the third curve served as the experimental concentration-response curve. Tissues were preincubated with ACE inhibitors for 10 mm before constructing the third curve
Name Type Language
INDOLAPRIL HYDROCHLORIDE
USAN  
USAN  
Official Name English
1H-INDOLE-2-CARBOXYLIC ACID, 1-(2-((1-(ETHOXYCARBONYL)-3-PHENYLPROPYL)AMINO)-1-OXOPROPYL)OCTAHYDRO-, MONOHYDROCHLORIDE, (2S-(1(R*(R*)),2.ALPHA.,3A.BETA.,7A.BETA.))-
Common Name English
CI-907
Code English
(2S,3aS,7aS)-1-[(S)-N-[(S)-1-Carboxy-3-phenylpropyl]alanyl]hexahydro-2-indolinecarboxylic acid, 1-ethyl ester, monohydrochloride
Common Name English
INDOLAPRIL HYDROCHLORIDE [USAN]
Common Name English
Code System Code Type Description
NCI_THESAURUS
C174892
Created by admin on Fri Dec 15 15:23:59 GMT 2023 , Edited by admin on Fri Dec 15 15:23:59 GMT 2023
PRIMARY
USAN
U-11
Created by admin on Fri Dec 15 15:23:59 GMT 2023 , Edited by admin on Fri Dec 15 15:23:59 GMT 2023
PRIMARY
ChEMBL
CHEMBL331369
Created by admin on Fri Dec 15 15:23:59 GMT 2023 , Edited by admin on Fri Dec 15 15:23:59 GMT 2023
PRIMARY
MESH
C038812
Created by admin on Fri Dec 15 15:23:59 GMT 2023 , Edited by admin on Fri Dec 15 15:23:59 GMT 2023
PRIMARY
FDA UNII
QMI2CZ2C4P
Created by admin on Fri Dec 15 15:23:59 GMT 2023 , Edited by admin on Fri Dec 15 15:23:59 GMT 2023
PRIMARY
CAS
80828-32-6
Created by admin on Fri Dec 15 15:23:59 GMT 2023 , Edited by admin on Fri Dec 15 15:23:59 GMT 2023
PRIMARY
PUBCHEM
10457278
Created by admin on Fri Dec 15 15:23:59 GMT 2023 , Edited by admin on Fri Dec 15 15:23:59 GMT 2023
PRIMARY